SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045

Antibody responses to SARS-CoV-2 in patients with COVID-19

Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,298

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,968

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614

Development of an inactivated vaccine candidate for SARS-CoV-2

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997

Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L., Chen, Q., Zhang, L., Zhong, Q., Zhang, X., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.03.039 · Cited by 421

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636

Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses

Zhou, R., To, K. K.-W., Wong, Y.-C., Liu, L., Zhou, B., Li, X., Huang, H., Mo, Y., Luk, T.-Y., Lau, T. T.-K., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.026 · Cited by 531

Antibody response to SARS-CoV-2 infection in humans: A systematic review

Post, N., Eddy, D., Huntley, C., van Schalkwyk, M. C., Shrotri, M., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244126 · Cited by 379

T cell response to SARS-CoV-2 infection in humans: A systematic review

Shrotri, M., van Schalkwyk, M. C., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245532 · Cited by 352

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Kreer, C., Zehner, M., Weber, T., Ercanoglu, M. S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P., Vanshylla, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.044 · Cited by 309

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

Xu, J., Xu, K. Y., Jung, S., Conte, A., Lieberman, J. A., Muecksch, F., Lorenzi, J. C. C., Park, S., Schmidt, F., Wang, Z., et al. (2021) · Nature · doi:10.1038/s41586-021-03676-z · Cited by 232

Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production

Chen, Y., Zuiani, A., Fischinger, S., Mullur, J., Atyeo, C. G., Travers, M. E., Lelis, F., Pullen, K. M., Martin, H., Tong, P., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.051 · Cited by 182

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

Joyce, M. G., King, H. A. D., Lakhal-Naouar, I., Ahmed, A., Peachman, K. K., Cincotta, C. M., Subra, C., Chen, R. E., Thomas, P. V., Chen, W., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi5735 · Cited by 163

Laboratory diagnosis of coronavirus disease-2019 (COVID-19)

Li, C., Zhao, C., Bao, J., Tang, B., Wang, Y., & Gu, B. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.045 · Cited by 160

High neutralizing antibody titer in intensive care unit patients with COVID-19

Liu, L., To, K. K., Chan, K., Wong, M. Y.-C., Zhou, R., Kwan, K., Fong, C. H.-Y., Chen, L., Choi, C. Y.-K., Lu, L., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1791738 · Cited by 135

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?

Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 123

Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays

Tang, M. S., Case, J. B., Franks, C. E., Chen, R. E., Anderson, N. W., Henderson, J. P., Diamond, M., Gronowski, A. M., & Farnsworth, C. W. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa211 · Cited by 113

Robust SARS-CoV-2 Infection in Nasal Turbinate Despite Systemic Neutralizing Antibody

Zhou, D., Chan, J. F., Zhou, B., Zhou, R., Li, S., Shan, S., Liu, L., Zhang, J., Chen, S. J., Chan, C. C., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.019 · Cited by 101

COVID-19 Antibody Tests: A Valuable Public Health Tool with Limited Relevance to Individuals

West, R., Kobokovich, A. L., Connell, N. D., & Grönvall, G. K. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.11.002 · Cited by 94

Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset

Xiang, T., Liang, B., Fang, Y., Lu, S., Li, S., Wang, H., Li, H., Yang, X., Shěn, S., Zhu, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708523 · Cited by 84

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

Batty, C. J., Heise, M. T., Bachelder, E. M., & Ainslie, K. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.006 · Cited by 86

Evaluation of antibody response after COVID‐19 vaccination of healthcare workers

Uysal, E. B., Gümüş, S., Bektöre, B., Bozkurt, H., & Gözalan, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27420 · Cited by 79

Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 SpikePreprint

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.17.153486 · Cited by 76

Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity

Koblischke, M., Traugott, M. T., Medits, I., Spitzer, F. S., Zoufaly, A., Weseslindtner, L., Simonitsch, C., Seitz, T., Hoepler, W., Puchhammer‐Stöckl, E., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.592629 · Cited by 73

Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination

Altawalah, H. (2021) · Vaccines · doi:10.3390/vaccines9080910 · Cited by 74

Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection

Silverstein, N. J., Wang, Y., Manickas-Hill, Z., Carbone, C., Dauphin, A., Boribong, B. P., Loiselle, M., Davis, J., Leonard, M. M., Kuri-Cervantes, L., et al. (2022) · eLife · doi:10.7554/elife.74681 · Cited by 73

Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant

Mlčochová, P., Collier, D. A., Ritchie, A. V., Assennato, S. M., Hosmillo, M. D. T., Goel, N., Meng, B., Chatterjee, K., Mendoza, V., Temperton, N. J., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100099 · Cited by 72

Advances in Neutralization Assays for SARS‐CoV‐2

Lu, Y., Jin, W., Li, Q., Hu, H., Lu, J., & Chen, Z. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13088 · Cited by 58

Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses

Banach, B. B., Cerutti, G., Fahad, A. S., Shen, C., de Souza, M. O., Katsamba, P. S., Tsybovsky, Y., Wang, P., Nair, M. S., Huang, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109771 · Cited by 56

Placental response to maternal SARS-CoV-2 infection

Mourad, M., Jacob, T., Sadovsky, E., Bejerano, S., Simone, G. S.-D., Bagalkot, T. R., Zucker, J. E., Yin, M. T., Chang, J. Y., Liu, L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93931-0 · Cited by 58

Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications

Abebe, E. C., & Dejenie, T. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055457 · Cited by 58

Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature

Cantoni, D. M., Wilkie, C., Bentley, E. M., Neto, M. M., Wright, E., Scott, S. D., Ray, S., Castillo‐Olivares, J., Heeney, J. L., Mattiuzzo, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1184362 · Cited by 62

Pathogenesis‐directed therapy of 2019 novel coronavirus disease

Stratton, C. W., Tang, Y., & Lu, H. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26610 · Cited by 59

SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality

Bryan, A. B., Fink, S. L., Gattuso, M. A., Pepper, G., Chaudhary, A., Wener, M. H., Morishima, C., Jerome, K. R., Mathias, P. C., & Greninger, A. L. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa535 · Cited by 45

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses

Wang, P., Casner, R. G., Nair, M. S., Yu, J., Guo, Y., Wang, M., Chan, J. F., Cerutti, G., Iketani, S., Liu, L., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2011623 · Cited by 43

Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays

Semmler, G., Traugott, M. T., Graninger, M., Hoepler, W., Seitz, T., Kelani, H., Karolyi, M., Pawelka, E., Cruz, S. A. D. L., Puchhammer‐Stöckl, E., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02890-20 · Cited by 41

COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review

Simnani, F. Z., Singh, D., & Kaur, R. (2021) · 3 Biotech · doi:10.1007/s13205-021-03076-0 · Cited by 35

Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2

Amjadi, M. F., O’Connell, S. E., Armbrust, T., Mergaert, A. M., Narpala, S., Halfmann, P., Bashar, S. J., Glover, C. R., Heffron, A. S., Taylor, A., et al. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100022 · Cited by 34

Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern

Gorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Николаевна, Б. Т., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00340-8 · Cited by 33

Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection

Yan, L., Liu, P., Li, X.-G., Zhou, S.-J., Li, H., Wang, Z.-Y., Shen, F., Lu, B., Long, Y., Xiao, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.803031 · Cited by 36

Detection of SARS-CoV-2 Using Antibody–Antigen Interactions with Graphene-Based Nanomechanical Resonator Sensors

Payandehpeyman, J., Parvini, N., Moradi, K., & Hashemian, N. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c00983 · Cited by 31

Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults

Wagner, A., Guzek, A., Ruff, J., Jasińska, J., Scheikl, U., Zwazl, I., Kundi, M., Stockinger, H. S. J., Farcet, M. R., Kreil, T. R., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00012-4 · Cited by 28

AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories

Zhang, Y. V., Wiencek, J. R., Meng, Q. H., Theel, E. S., Babić, N., Sepiashvili, L., Pecora, N., Slev, P. R., Cameron, A., & Konforte, D. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab051 · Cited by 27

Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples

Szymczak, A., Jędruchniewicz, N., Torelli, A., Kaczmarzyk-Radka, A., Coluccio, R., Kłak, M., Konieczny, A., Ferenc, S., Witkiewicz, W., Montomoli, E., et al. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001692 · Cited by 26

SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia

Vilibić‐Čavlek, T., Stevanović, V., Ilić, M., Barbić, L., Capak, K., Tabain, I., Krleža, J. L., Ferenc, T., Hruškar, Ž., Topić, R. Z., et al. (2021) · Pathogens · doi:10.3390/pathogens10060774 · Cited by 24

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Winckelmann, A. A., Bollerup, S., Mikkelsen, L. S., Sørensen, A.-L., Feng, S., Fahnøe, U., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103519 · Cited by 23

Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China

Feng, X., Yin, J., Zhang, J., Hu, Y., Ouyang, Y., Qiao, S., Zhao, H., Zhang, T., Li, X., Zhang, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614436 · Cited by 22

Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study

Moradi, G., Bolbanabad, A. M., Ahmadi, S., Aghaei, A., Bahrami, F., Veysi, A., Kalmarzi, R. N., Shokri, A., Ghaderi, E., Mohsenpour, B., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107893 · Cited by 22

SARS-CoV-2 RNA Shedding in Semen and Oligozoospermia of Patient with Severe Coronavirus Disease 11 Weeks after Infection

Purpura, L. J., Alukal, J. P., Chong, A. M., Liu, L., Cantos, A., Shah, J., Medrano, N., Chang, J. Y., Tsuji, M., Mohri, H., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2801.211521 · Cited by 22

COVID-19 as an Immune Complex Hypersensitivity in Antigen Excess Conditions: Theoretical Pathogenetic Process and Suggestions for Potential Therapeutic Interventions

Manzo, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.566000 · Cited by 21

A longitudinal study of convalescent plasma ( CCP ) donors and correlation of ABO group, initial neutralizing antibodies ( nAb ), and body mass index ( BMI ) with nAb and anti‐nucleocapsid ( NP ) SARS‐CoV ‐2 antibody kinetics: Proposals for better quality of CCP collections

Wendel, S., Fontão‐Wendel, R., Fachini, R. M., Candelaria, G. D. T. P., Scuracchio, P., Achkar, R., Brito, M., Reis, L. F. L., Camargo, A. A., Amano, M. T., et al. (2021) · Transfusion · doi:10.1111/trf.16323 · Cited by 21

Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study

Karuna, S., Li, S. S., Grant, S., Walsh, S. R., Frank, I., Casapía, M., Trahey, M., Hyrien, O., Fisher, L. H., Miner, M. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003868 · Cited by 21

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Mikkelsen, L. S., Fahnøe, U., Bollerup, S., Winckelmann, A. A., Schneider, U. V., Binderup, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104475 · Cited by 21

Cardiopulmonary rehabilitation programme improves physical health and quality of life in post-COVID syndrome

Szarvas, Z., Fekete, M., Horvath, R., Shimizu, M., Tsuhiya, F., Choi, H. E., Kup, K., Fazekas‐Pongor, V., Pete, K. N., Cserjési, R., et al. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1143 · Cited by 24

Potential mechanisms of action of convalescent plasma in COVID-19

Franchini, M., Glingani, C., & Liumbruno, G. M. (2021) · Diagnosis · doi:10.1515/dx-2020-0161 · Cited by 21

Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds

Cantoni, D. M., Neto, M. M., Nadesalingam, A., Wells, D. A., Carnell, G., Ohlendorf, L., Ferrari, M., Palmer, P., Chan, A. C. Y., Smith, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.773982 · Cited by 20

Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India

Shrivastava, S., Palkar, S. H., Shah, J. N., Rane, P. S., Lalwani, S. K., Mishra, A. C., & Arankalle, V. A. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0014 · Cited by 20

Convalescent plasma treatment of critically ill intensive care COVID ‐19 patients

Lindemann, M., Lenz, V., Knop, D., Klump, H., Alt, M., Aufderhorst, U. W., Schipper, L., Schwarzkopf, S., Meller, L., Steckel, N. K., et al. (2021) · Transfusion · doi:10.1111/trf.16392 · Cited by 18

Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults

Jónsdóttir, H. R., Bielecki, M., Siegrist, D., Buehrer, T. W., Züst, R., & Deuel, J. (2021) · Viruses · doi:10.3390/v13020284 · Cited by 17

Emerging Trends in the Epidemiology of COVID-19: The Croatian ‘One Health’ Perspective

Vilibić‐Čavlek, T., Stevanović, V., Brlek-Gorski, D., Ferenčak, I., Ferenc, T., Bošnjak, M. U., Tabain, I., Janev-Holcer, N., Perković, I., Anticevic, M., et al. (2021) · Viruses · doi:10.3390/v13122354 · Cited by 15

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 Vaccines

Sølund, C. S., Underwood, A. P., Fernandez-Antunez, C., Bollerup, S., Mikkelsen, L. S., Villadsen, S. L., Fahnøe, U., Winckelmann, A. A., Feng, S., Vinten, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10010075 · Cited by 15

Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients

Zavaglio, F., Frangipane, V., Morosini, M., Gabanti, E., Zelini, P., Sammartino, J. C., Ferrari, A., Gregorini, M., Rampino, T., Asti, A., et al. (2021) · Viruses · doi:10.3390/v13112261 · Cited by 14

Does the COVID‐19 seroconversion in older adults resemble the young?

Soytaş, R. B., Cengız, M., İslamoğlu, M. S., Uysal, B. B., İkitimur, H., Yavuzer, H., & Yavuzer, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27106 · Cited by 13

Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection

Tyner, H. L., Burgess, J. L., Grant, L., Gaglani, M., Kuntz, J. L., Naleway, A. L., Thornburg, N. J., Caban-Martinez, A. J., Yoon, S. K., Herring, M. K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1038 · Cited by 13

Measurement of SARS-CoV-2 Antibody Titers Improves the Prediction Accuracy of COVID-19 Maximum Severity by Machine Learning in Non-Vaccinated Patients

Kurano, M., Ohmiya, H., Kishi, Y., Okada, J., Nakano, Y., Yokoyama, R., Qian, C., Xia, F., He, F., Zheng, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.811952 · Cited by 13

Towards a Future of Personalized Vaccinology: Study on Individual Variables Influencing the Antibody Response to the COVID-19 Vaccine

Visalli, G., Laganà, A., Giudice, D. L., Calimeri, S., Caccamo, D., Trainito, A., Pietro, A. D., & Facciolà, A. (2023) · Vaccines · doi:10.3390/vaccines11020217 · Cited by 13

Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19

Chen, J., Huang, R., Nie, Y., Wen, X., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00327-x · Cited by 12

Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review

Ramachandran, A. K., Das, S., & Joseph, A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210113154342 · Cited by 12

Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen

Srivastava, V., Niu, L., Phadke, K. S., Bellaire, B. H., & Cho, M. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637982 · Cited by 11

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Kandula, U. R., Tuji, T. S., Gudeta, D. B., Leta, K., Abdulwahed, A., Diriba, K., & Abbas, A. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s397722 · Cited by 11

Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19–convalescent individuals

Min, L., Liu, J., Lu, R., Zhang, Y., Du, M., Xing, M., Wu, Z., Kong, X., Zhu, Y., Zhou, X., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.005 · Cited by 10

Prolonged severe acute respiratory syndrome coronavirus 2 persistence, attenuated immunologic response, and viral evolution in a solid organ transplant patient

Purpura, L. J., Chang, M., Annavajhala, M. K., Mohri, H., Liu, L., Shah, J., Cantos, A., Medrano, N., Laracy, J. C., Scully, B. E., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16837 · Cited by 10

Practical Considerations for Implementation of SARS-CoV-2 Serological Testing in the Clinical Laboratory: Experience at an Academic Medical Center

Humble, R. M., Merrill, A. E., Ford, B. A., Diekema, D. J., & Krasowski, M. D. (2021) · Academic Pathology · doi:10.1177/23742895211002802 · Cited by 10

Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting

McCance, K., Wise, H. M., Simpson, J., Batchelor, B., Hale, H., McDonald, L., Zorzoli, A., Furrie, E., Chopra, C., Muecksch, F., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266086 · Cited by 9

How IvIg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model

Köhler, H., & Kaveri, S. V. (2021) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2020.0041 · Cited by 8

The solid organ transplant recipient with SARS-CoV-2 infection

Laracy, J. C., Miko, B. A., & Pereira, M. R. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000888 · Cited by 8

Antibody responses in COVID-19 patients

Liu, S., & Lu, S. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200134 · Cited by 8

SARS-CoV-2 Antibody Testing: Where Are We Now?

Smerczak, E. (2021) · Laboratory Medicine · doi:10.1093/labmed/lmab061 · Cited by 8

Severe Acute Respiratory Syndrome Coronavirus‐2

Slev, P. R. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch54 · Cited by 8

Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant

Lee, B., Ko, J., Baek, J. Y., Kim, H., Huh, K., Cho, S. Y., Kang, C., Chung, D. R., Peck, K. R., & Kang, E. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e292 · Cited by 7

Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study

Violán, C., Torán‐Monserrat, P., Quirant‐Sánchez, B., Lamonja-Vicente, N., Carrasco-Ribelles, L. A., Chacón, C., Manresa‐Domínguez, J. M., Ramos‐Roure, F., Dacosta‐Aguayo, R., Palacios-Fernández, C., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07696-6 · Cited by 7

How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?

Pons, S., Uhel, F., Frapy, E., Sérémé, Y., Zafrani, L., Aschard, H., & Skurnik, D. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10477-y · Cited by 6

Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model

Uematsu, T., Takano, T., Matsui, H., Kobayashi, N., Ōmura, S., & Hanaki, H. (2023) · The Journal of Antibiotics · doi:10.1038/s41429-023-00623-0 · Cited by 8

Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation

Pinski, A. N., Steffen, T. L., Zulu, M. Z., George, S. L., Dickson, A., Tifrea, D., Maroney, K. J., Tedeschi, N., Zhang, Y., Scheuermann, R. H., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4cova0121-084rr · Cited by 6

The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal

Tosta, E. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00014 · Cited by 5

Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost

Nair, M. S., Ribeiro, R. M., Wang, M., Bowen, A. D., Liu, L., Guo, Y., Chang, J. Y., Wang, P., Sheng, Z., Sobieszczyk, M. E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106345 · Cited by 5

Vaccinomics and adversomics: key elements for a personalized vaccinology

Laganà, A., Visalli, G., Pietro, A. D., & Facciolà, A. (2024) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2024.13.2.105 · Cited by 5

mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19

Zavaglio, F., Cassaniti, I., Sammartino, J. C., Tonello, S., Sainaghi, P. P., Novelli, V., Meloni, F., Lilleri, D., & Baldanti, F. (2022) · Microorganisms · doi:10.3390/microorganisms10061250 · Cited by 4

Factors Associated with SARS-CoV-2 Repeat Positivity — Beijing, China, June–September 2020

Li, S., Wang, X., Li, L., Pan, Y., Yang, S., Tan, D., Shen, Y., Yang, P., Bar‐Zeev, N., Hu, Y., et al. (2022) · China CDC Weekly · doi:10.46234/ccdcw2022.017 · Cited by 4

Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?

Ravlić, S., Hečimović, A., Kurtović, T., Ivančić-Jelečki, J., Forčić, D., Slović, A., Kurolt, I.-C., Šafranko, Ž. M., Mušlin, T., Rnjak, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816159 · Cited by 4

Phylodynamic analysis revealed that human mobility and vaccination were correlated to the local spread of SARS-CoV-2 in Republic of Korea

Lee, S., Lee, D., Kim, J., Kim, D.-W., Kim, J., Kim, J.-A., Kim, I., Rhee, J. E., Min, K., Cho, S., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2228934 · Cited by 3

Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Belem, W. F., Liu, C., Hu, Y.-T., Burnouf, T. P. R., & Lin, L. (2022) · Viruses · doi:10.3390/v14112419 · Cited by 3

Antibody kinetics to SARS-CoV-2 at 13.5 months, by disease severityPreprint

Violán, C., Torán‐Monserrat, P., Quirant‐Sánchez, B., Lamonja-Vicente, N., Carrasco-Ribelles, L. A., Chacón, C., Manresa‐Domínguez, J. M., Ramos‐Roure, F., Roso‐Llorach, A., Pujol, A., et al. (2021) · medRxiv · doi:10.1101/2021.09.10.21262527 · Cited by 3

Determinants and dynamics of the seroprevalence of anti-SARS-CoV-2 antibodies in Poland

Adamczuk, J., Kamiński, K. A., Sołomacha, S., Kazberuk, M., Chlabicz, M., Czupryna, P., Dunaj, J., Citko, A., Sowa, P., Dubatówka, M., et al. (2025) · Advances in Medical Sciences · doi:10.1016/j.advms.2025.03.002 · Cited by 2

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern

Griffin, A. J., O’Donnell, K. L., Shifflett, K., Lavik, J., Russell, P. M., Zimmerman, M. K., Relich, R. F., & Marzi, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-07960-4 · Cited by 2

COVID-19 Infection, Vaccination, and Antibody Levels: Investigating Correlations through a Cohort Study

Kayalı, G. A., Durmaz, S., Şahin, İ. N., Akkul, B., Durusoy, R., Akarca, F. K., Ulukaya, S., & Çiçek, C. (2023) · Vaccines · doi:10.3390/vaccines11071258 · Cited by 2

Good news from Alsace: the Covid-19 pandemic is (almost) over. NOW WHAT?Preprint

Rodríguez, C. (2020) · doi:10.32388/uo6rt1.2 · Cited by 2

Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials

Lofgren, S. M., Okafor, E. C., Colette, A. A., Pastick, K. A., Skipper, C. P., Pullen, M. F., Nicol, M. R., Bold, T. D., Bangdiwala, A. S., Engen, N. W., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab506 · Cited by 1

Symptomatic and Asymptomatic SARS-CoV-2 Infection and Follow-up of Neutralizing Antibody Levels.

Cui, S., Zhang, Y., Gao, W. J., Wang, X. L., Yang, P., Wang, Q. Y., Pang, X., Zeng, X. P., & Li, L. M. (2022) · PubMed Central · doi:10.3967/bes2022.139 · Cited by 1

Temporal pattern of humoral immune response in mild cases of COVID-19

Campos, I. M. P., Marques, M., Peiter, G. C., Brandalize, A. P. C., dos Santos, M. B., de Melo, F. F., & Teixeira, K. N. (2023) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v14.i2.40 · Cited by 1

Comparative Analysis of Nucleocapsid Antibody Levels, Neutralizing Antibodies, and Spike Receptor-binding Domain in Severe Acute Respiratory Syndrome Coronavirus-2 Patients

Prasetiyanti, R., Fitriah, M., Azmi, Y. A., Soetanto, K. M., & Castillo, M. (2024) · Biomolecular and Health Science Journal · doi:10.4103/bhsj.bhsj_49_23 · Cited by 1

Differential immune profiles in elderly patients with non-severe versus severe SARS-CoV-2 omicron variant infection: dysregulation of antibody responses and B-cell subsets

Li, X., Li, Y., Liu, S., Zhou, J., Yang, X., Yang, J., Xu, W., & Chen, W. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00543-7 · Cited by 1

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Trinité, B., Tarrés-Freixas, F., Rodon, J., Pradenas, E., Urrea, V., Marfil, S., de la Concepción, M. L. R., Ávila‐Nieto, C., Aguilar‐Gurrieri, C., Barajas, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81862-9 · Cited by 104

Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Rijkers, G. T., Murk, J., Wintermans, B., van Looy, B., van den Berge, M., Veenemans, J., Stohr, J., Reusken, C. B. E. M., van der Pol, P., & Reimerink, J. H. J. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa463 · Cited by 175

Investigation and long‐term monitoring of the presence of neutralizing antibody in patients with COVID‐19 disease of different clinical severity

Kaygusuz, S., Korukluoğlu, G., Coşgun, Y., Şahin, Ö., & Arslan, F. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27751 · Cited by 8

Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

Serna-Muñoz, R., Hernández‐Terán, A., Soto-Nava, M., Tapia‐Trejo, D., Ávila‐Ríos, S., Mejía-Nepomuceno, F., García, E., Castillejos-López, M. D. J., Higuera-Iglesias, A. L., Aquino‐Gálvez, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122063 · Cited by 3

Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients

Patil, H. P., Rane, P. S., Shrivastava, S., Palkar, S. H., Lalwani, S. K., Mishra, A. C., & Arankalle, V. A. (2021) · Viral Immunology · doi:10.1089/vim.2020.0321 · Cited by 36